NovoCure Limited Research and Development Expense
NovoCure Limited (NVCR) reported Research and Development Expense of $51.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-23
- NovoCure Limited research and development expense for the quarter ending 2026-06-30 was $51.45M, a 7.85% decline year-over-year.
- NovoCure Limited research and development expense for the quarter ending 2026-03-31 was $58.34M, a 8.48% increase year-over-year.
- NovoCure Limited research and development expense for the quarter ending 2025-12-31 was $60.91M, a 18.93% increase year-over-year.
- NovoCure Limited research and development expense for the quarter ending 2025-09-30 was $54.03M, a 4.14% increase year-over-year.
- NovoCure Limited research and development expense for fiscal 2024 was $209.65M, a 6.01% decline from fiscal 2023.
- NovoCure Limited research and development expense for fiscal 2023 was $223.06M, a 8.24% increase from fiscal 2022.
- NovoCure Limited research and development expense for fiscal 2022 was $206.09M, a 2.38% increase from fiscal 2021.
- NovoCure Limited research and development expense for fiscal 2021 was $201.30M, a 52.49% increase from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $51.45M 10-Q · filed 2026-07-23 | $109.78M 10-Q · filed 2026-07-23 | $170.69M derived: sum of 3 quarters · filed 2026-07-23 | $224.72M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $58.34M 10-Q · filed 2026-04-30 | $119.24M derived: sum of 2 quarters · filed 2026-07-23 | $173.27M derived: sum of 3 quarters · filed 2026-07-23 | $229.10M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $60.91M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-23 | $114.93M derived: sum of 2 quarters · filed 2026-07-23 | $170.77M derived: sum of 3 quarters · filed 2026-07-23 | $224.54M 10-Q · filed 2026-07-23 |
| 2025-09-30 | $54.03M 10-Q · filed 2025-10-30 | $109.86M derived: sum of 2 quarters · filed 2026-07-23 | $163.64M 10-Q · filed 2025-10-30 | $214.85M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $55.83M 10-Q · filed 2026-07-23 | $109.61M 10-Q · filed 2026-07-23 | $160.82M derived: sum of 3 quarters · filed 2026-07-23 | $212.70M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $53.78M 10-Q · filed 2026-04-30 | $104.99M derived: sum of 2 quarters · filed 2026-04-30 | $156.87M derived: sum of 3 quarters · filed 2026-04-30 | $211.82M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $51.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $103.09M derived: sum of 2 quarters · filed 2026-02-26 | $158.05M derived: sum of 3 quarters · filed 2026-02-26 | $209.65M 10-K · filed 2026-02-26 |
| 2024-09-30 | $51.88M 10-Q · filed 2025-10-30 | $106.84M derived: sum of 2 quarters · filed 2025-10-30 | $158.44M 10-Q · filed 2025-10-30 | $212.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $54.95M 10-Q · filed 2025-07-24 | $106.55M 10-Q · filed 2025-07-24 | $160.86M derived: sum of 3 quarters · filed 2026-02-26 | $214.48M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $51.60M 10-Q · filed 2025-04-24 | $105.91M derived: sum of 2 quarters · filed 2026-02-26 | $159.53M derived: sum of 3 quarters · filed 2026-02-26 | $214.96M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $54.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $107.93M derived: sum of 2 quarters · filed 2026-02-26 | $163.36M derived: sum of 3 quarters · filed 2026-02-26 | $223.06M 10-K · filed 2026-02-26 |
| 2023-09-30 | $53.62M 10-Q · filed 2024-10-30 | $109.05M derived: sum of 2 quarters · filed 2024-10-30 | $168.75M 10-Q · filed 2024-10-30 | $223.57M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $55.43M 10-Q · filed 2024-07-25 | $115.13M 10-Q · filed 2024-07-25 | $169.95M derived: sum of 3 quarters · filed 2025-02-27 | $221.91M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $59.70M 10-Q · filed 2024-05-02 | $114.52M derived: sum of 2 quarters · filed 2025-02-27 | $166.48M derived: sum of 3 quarters · filed 2025-02-27 | $223.56M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $54.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $106.78M derived: sum of 2 quarters · filed 2025-02-27 | $163.85M derived: sum of 3 quarters · filed 2025-02-27 | $206.09M 10-K · filed 2025-02-27 |
| 2022-09-30 | $51.96M 10-Q · filed 2023-10-26 | $109.03M derived: sum of 2 quarters · filed 2023-10-26 | $151.26M 10-Q · filed 2023-10-26 | $208.20M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $57.08M 10-Q · filed 2023-07-27 | $99.31M 10-Q · filed 2023-07-27 | $156.24M derived: sum of 3 quarters · filed 2024-02-22 | $204.38M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $42.23M 10-Q · filed 2023-05-04 | $99.17M derived: sum of 2 quarters · filed 2024-02-22 | $147.31M derived: sum of 3 quarters · filed 2024-02-22 | $197.62M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $56.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $105.07M derived: sum of 2 quarters · filed 2024-02-22 | $155.39M derived: sum of 3 quarters · filed 2024-02-22 | $201.30M 10-K · filed 2024-02-22 |
| 2021-09-30 | $48.14M 10-Q · filed 2022-10-27 | $98.46M derived: sum of 2 quarters · filed 2022-10-27 | $144.37M 10-Q · filed 2022-10-27 | $188.37M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $50.31M 10-Q · filed 2022-07-28 | $96.23M 10-Q · filed 2022-07-28 | $140.23M derived: sum of 3 quarters · filed 2023-02-23 | $173.05M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $45.92M 10-Q · filed 2022-04-28 | $89.92M derived: sum of 2 quarters · filed 2023-02-23 | $122.74M derived: sum of 3 quarters · filed 2023-02-23 | $152.65M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $44.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $76.82M derived: sum of 2 quarters · filed 2023-02-23 | $106.74M derived: sum of 3 quarters · filed 2023-02-23 | $132.01M 10-K · filed 2023-02-23 |
| 2020-09-30 | $32.82M 10-Q · filed 2021-10-28 | $62.74M derived: sum of 2 quarters · filed 2021-10-28 | $88.01M 10-Q · filed 2021-10-28 | $111.75M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $29.92M 10-Q · filed 2021-07-29 | $55.19M 10-Q · filed 2021-07-29 | $78.93M derived: sum of 3 quarters · filed 2022-02-24 | $97.70M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $25.27M 10-Q · filed 2021-04-29 | $49.01M derived: sum of 2 quarters · filed 2022-02-24 | $67.78M derived: sum of 3 quarters · filed 2022-02-24 | $87.23M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $23.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $42.51M derived: sum of 2 quarters · filed 2022-02-24 | $61.96M derived: sum of 3 quarters · filed 2022-02-24 | $79.00M 10-K · filed 2022-02-24 |
| 2019-09-30 | $18.77M 10-Q · filed 2020-10-29 | $38.22M derived: sum of 2 quarters · filed 2020-10-29 | $55.26M 10-Q · filed 2020-10-29 | $70.30M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $19.45M 10-Q/A · filed 2020-10-02 | $36.50M 10-Q/A · filed 2020-10-02 | $51.53M derived: sum of 3 quarters · filed 2021-02-25 | $64.60M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $17.04M 10-Q/A · filed 2020-10-02 | $32.08M derived: sum of 2 quarters · filed 2021-02-25 | $45.15M derived: sum of 3 quarters · filed 2021-02-25 | $56.51M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $15.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $28.11M derived: sum of 2 quarters · filed 2021-02-25 | $39.47M derived: sum of 3 quarters · filed 2021-02-25 | $50.57M 10-K · filed 2021-02-25 |
| 2018-09-30 | $13.07M 10-Q · filed 2019-10-31 | $24.44M derived: sum of 2 quarters · filed 2019-10-31 | $35.54M 10-Q · filed 2019-10-31 | $45.59M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $11.36M 10-Q · filed 2019-07-25 | $22.47M 10-Q · filed 2019-07-25 | $32.51M derived: sum of 3 quarters · filed 2020-02-27 | $41.79M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $11.10M 10-Q · filed 2019-05-02 | $21.15M derived: sum of 2 quarters · filed 2020-02-27 | $30.43M derived: sum of 3 quarters · filed 2020-02-27 | $39.80M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $10.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $19.32M derived: sum of 2 quarters · filed 2020-02-27 | $28.69M derived: sum of 3 quarters · filed 2020-02-27 | $38.10M 10-K · filed 2020-02-27 |
| 2017-09-30 | $9.27M 10-Q · filed 2018-10-25 | $18.64M derived: sum of 2 quarters · filed 2018-10-25 | $28.05M 10-Q · filed 2018-10-25 | $36.53M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $9.37M 10-Q · filed 2018-07-26 | $18.78M 10-Q · filed 2018-07-26 | $27.25M derived: sum of 3 quarters · filed 2019-02-28 | $37.49M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $9.41M 10-Q · filed 2018-04-26 | $17.88M derived: sum of 2 quarters · filed 2019-02-28 | $28.11M derived: sum of 3 quarters · filed 2019-02-28 | $39.43M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $18.70M derived: sum of 2 quarters · filed 2019-02-28 | $30.02M derived: sum of 3 quarters · filed 2019-02-28 | $41.47M 10-K · filed 2019-02-28 |
| 2016-09-30 | $10.23M 10-Q · filed 2017-10-26 | $21.55M derived: sum of 2 quarters · filed 2017-10-26 | $33.00M 10-Q · filed 2017-10-26 | $43.84M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-06-30 | $11.32M 10-Q · filed 2017-07-27 | $22.76M 10-Q · filed 2017-07-27 | $33.61M derived: sum of 3 quarters · filed 2018-02-22 | $43.82M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-03-31 | $11.45M 10-Q · filed 2017-04-27 | $22.29M derived: sum of 2 quarters · filed 2018-02-22 | $32.50M derived: sum of 3 quarters · filed 2018-02-22 | $45.27M derived: sum of 4 quarters · filed 2018-02-22 |
| 2015-12-31 | $10.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $21.06M derived: sum of 2 quarters · filed 2018-02-22 | $33.82M derived: sum of 3 quarters · filed 2018-02-22 | $43.75M 10-K · filed 2018-02-22 |
| 2015-09-30 | $10.21M 10-Q · filed 2016-11-02 | $22.98M derived: sum of 2 quarters · filed 2016-11-02 | $32.90M 10-Q · filed 2016-11-02 | $44.09M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $12.77M 10-Q · filed 2016-07-28 | $22.69M 10-Q · filed 2016-07-28 | $33.88M derived: sum of 3 quarters · filed 2017-02-23 | $43.16M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $9.93M 10-Q · filed 2016-05-10 | $21.12M derived: sum of 2 quarters · filed 2017-02-23 | $30.39M derived: sum of 3 quarters · filed 2017-02-23 | |
| 2014-12-31 | $11.19M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $20.47M derived: sum of 2 quarters · filed 2017-02-23 | $40.38M 10-K · filed 2017-02-23 | |
| 2014-09-30 | $9.28M 10-Q · filed 2015-10-27 | $29.19M 10-Q · filed 2015-10-27 | ||
| 2013-12-31 | $34.80M 10-K · filed 2016-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |